---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-013264"
form_type: "8-K"
ticker: null
cik: "0001106838"
company_name: "Sonnet BioTherapeutics Holdings, Inc."
filed_at: "2025-06-02T23:59:59+00:00"
generated_at: "2026-05-20T02:24:53.225159+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# SONN reports stockholders' equity of $662K, below Nasdaq $2.5M minimum; faces delisting risk

## Summary
- Stockholders' equity of $662,262 as of March 31, 2025, well below the $2.5M minimum for continued Nasdaq listing.
- Must submit a compliance plan by July 14, 2025; Nasdaq may grant an up to 180-day extension if plan accepted.
- Also fails alternative compliance measures: market value of listed securities <$35M and no net income >$500K.
- No immediate effect on trading; common stock (SONN) continues on Nasdaq Capital Market.
- Delisting would materially hurt capital raising, liquidity, and stock value.

## SEC filing metadata
- accession: 0001641172-25-013264
- form_type: 8-K
- cik: 0001106838
- company_name: Sonnet BioTherapeutics Holdings, Inc.
- filed_at: 2025-06-02T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1106838/000164117225013264/0001641172-25-013264-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1106838/000164117225013264/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-013264
- JSON: https://secwatch.observer/filing/0001641172-25-013264.json
- Plain text: https://secwatch.observer/filing/0001641172-25-013264.txt

## Key facts
- Listing & Compliance Notices
  Sonnet BioTherapeutics Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: stockholders equity
  - Rules: 5550(b)(1)
  source text: May 30, 2025, Sonnet BioTherapeutics Holdings, Inc. (the “Company”) received notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) advising the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(b)(1) requires companies listed on The Nasdaq Capital Market to maintain stockholders’ equity of at least $2,500,000 (the “Stockholders’ Equity Requirement”). In the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, the Company reported stockholders’ e
  evidence_url: https://www.sec.gov/Archives/edgar/data/1106838/000164117225013264/0001641172-25-013264-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.